Analysts expect that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will post earnings per share of ($1.22) for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.80). Ultragenyx Pharmaceutical reported earnings of ($2.04) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 40.2%. The firm is scheduled to issue its next earnings results on Wednesday, May 5th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($4.81) per share for the current year, with EPS estimates ranging from ($5.69) to ($3.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($4.21) per share, with EPS estimates ranging from ($6.04) to ($1.22). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Ultragenyx Pharmaceutical.
A number of equities research analysts have weighed in on the company. TheStreet upgraded Ultragenyx Pharmaceutical from a “d” rating to a “c-” rating in a research report on Tuesday, February 16th. Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating and set a $152.00 target price for the company. in a research note on Wednesday, February 17th. Credit Suisse Group lifted their target price on Ultragenyx Pharmaceutical from $64.00 to $99.00 and gave the stock a “neutral” rating in a report on Monday, January 25th. Piper Sandler upped their price target on shares of Ultragenyx Pharmaceutical from $165.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, February 12th. Finally, Stifel Nicolaus assumed coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, March 1st. They issued a “buy” rating and a $179.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $132.50.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 30,000 shares of the business’s stock in a transaction dated Monday, March 1st. The stock was sold at an average price of $141.80, for a total value of $4,254,000.00. Following the completion of the sale, the chief executive officer now owns 596,941 shares of the company’s stock, valued at $84,646,233.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director William Aliski sold 7,500 shares of the company’s stock in a transaction dated Friday, February 19th. The stock was sold at an average price of $149.01, for a total value of $1,117,575.00. Following the sale, the director now owns 73,204 shares of the company’s stock, valued at approximately $10,908,128.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,245 shares of company stock worth $7,637,704. Insiders own 8.20% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $77,444,000. UBS Asset Management Americas Inc. grew its position in shares of Ultragenyx Pharmaceutical by 4.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 68,401 shares of the biopharmaceutical company’s stock valued at $9,469,000 after purchasing an additional 3,066 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Ultragenyx Pharmaceutical by 89.3% in the fourth quarter. Hsbc Holdings PLC now owns 9,962 shares of the biopharmaceutical company’s stock worth $1,397,000 after purchasing an additional 4,699 shares during the period. Virtu Financial LLC bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter worth about $1,966,000. Finally, WCM Investment Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 5.8% during the 4th quarter. WCM Investment Management LLC now owns 71,729 shares of the biopharmaceutical company’s stock worth $9,929,000 after purchasing an additional 3,917 shares during the last quarter.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.
See Also: Rule of 72
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.